Chemed (NYSE:CHE) Stock: Insider Spencer Lee Sells 920 Shares

Chemed Corporation (NYSE:CHE) EVP Spencer Lee sold 920 shares of the firm’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $537.17, for a total value of $494,196.40. Following the completion of the transaction, the executive vice president directly owned 13,931 shares in the company, valued at $7,483,315.27. This trade represents a 6.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Chemed Trading Up 2.9%

Shares of CHE opened at $548.87 on Thursday. Chemed Corporation has a 12 month low of $365.20 and a 12 month high of $562.24. The stock’s 50-day moving average is $514.63 and its two-hundred day moving average is $464.29. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.11 and a quick ratio of 1.08. The stock has a market cap of $7.15 billion, a PE ratio of 26.26, a P/E/G ratio of 2.03 and a beta of 0.50.

Chemed (NYSE:CHE) last posted its earnings results on Tuesday, October 27th. The company reported $6.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.44 by $0.31. The business had revenue of $690.94 million during the quarter, compared to analyst estimates of $685.04 million. Chemed had a return on equity of 35.18% and a net margin of 10.61%. The company’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same quarter last year, the firm earned $5.27 earnings per share. Equities analysts forecast that Chemed Corporation will post 24.05 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on CHE shares. Bank of America reiterated a “neutral” rating on shares of Chemed in a research note on Wednesday, July 29th. Jefferies Financial Group upgraded shares of Chemed from a “hold” rating to a “buy” rating and upped their target price for the company from $520.00 to $620.00 in a research note on Wednesday, October 28th. Wall Street Zen raised shares of Chemed from a “buy” rating to a “strong-buy” rating in a report on Saturday, October 10th. Oppenheimer lifted their price target on shares of Chemed from $590.00 to $625.00 and gave the stock an “outperform” rating in a research note on Thursday, October 29th. Finally, UBS Group lifted their price target on shares of Chemed from $650.00 to $675.00 and gave the stock a “buy” rating in a research note on Thursday, October 29th. Three investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $603.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. acquired a new position in Chemed during the 2nd quarter worth $691,290,000. Bank of America Corp DE bought a new stake in shares of Chemed in the 2nd quarter worth about $48,255,000. Caisse de depot et placement du Quebec bought a new stake in shares of Chemed in the 2nd quarter worth about $44,309,000. Bank of New York Mellon Corp acquired a new stake in shares of Chemed in the 2nd quarter valued at about $43,800,000. Finally, First Trust Advisors LP raised its stake in shares of Chemed by 24.7% in the 1st quarter. First Trust Advisors LP now owns 236,392 shares of the company’s stock valued at $89,295,000 after purchasing an additional 46,791 shares in the last quarter. Hedge funds and other institutional investors own 95.85% of the company’s stock.

About Chemed

Chemed Corporation (NYSE:CHE) is a Cincinnati, Ohio-based company that provides healthcare and residential and commercial services through two operating businesses: VITAS Healthcare and Roto-Rooter. Its operations serve customers primarily in the United States, with Roto-Rooter also providing services in Canada.

VITAS Healthcare is a provider of hospice and palliative care for individuals with advanced illnesses. The business delivers care in patients’ homes, hospice inpatient units, hospitals, nursing facilities and other care settings.